These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 8520332)

  • 21. Patient and parental attitudes toward genetic screening and its implications at an adult cystic fibrosis centre.
    Conway SP; Allenby K; Pond MN
    Clin Genet; 1994 Jun; 45(6):308-12. PubMed ID: 7923862
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost effectiveness of antenatal screening for cystic fibrosis. Couple screening would be easier for many centres.
    Doherty RA; Bradley LA; Haddow JE
    BMJ; 1996 Apr; 312(7035):909; author reply 910. PubMed ID: 8611896
    [No Abstract]   [Full Text] [Related]  

  • 23. Cost effectiveness of antenatal screening for cystic fibrosis. Study might be better described as a cost description of screening.
    Walters S
    BMJ; 1996 Apr; 312(7035):909-10. PubMed ID: 8611897
    [No Abstract]   [Full Text] [Related]  

  • 24. Acceptability of carrier screening for cystic fibrosis during pregnancy in a German population.
    Jung U; Urner U; Grade K; Coutelle C
    Hum Genet; 1994 Jul; 94(1):19-24. PubMed ID: 8034290
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Direct marketing of cystic fibrosis carrier screening: commercial push or population need?
    Cuckle H; Lilford R; Wilson J; Sehmi I
    J Med Genet; 1995 Sep; 32(9):758. PubMed ID: 8544204
    [No Abstract]   [Full Text] [Related]  

  • 26. Cost effectiveness of antenatal screening for cystic fibrosis. Authors should have used marginal analysis.
    Torgerson DJ
    BMJ; 1996 Apr; 312(7035):909; author reply 910. PubMed ID: 8611895
    [No Abstract]   [Full Text] [Related]  

  • 27. Prenatal screening for cystic fibrosis carriers: an economic evaluation.
    Rowley PT; Loader S; Kaplan RM
    Am J Hum Genet; 1998 Oct; 63(4):1160-74. PubMed ID: 9758600
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Screening for carriers of cystic fibrosis--a general practitioner's perspective.
    Modell M
    BMJ; 1993 Oct; 307(6908):849-52. PubMed ID: 8401130
    [TBL] [Abstract][Full Text] [Related]  

  • 29. "Suddenly Having two Positive People who are Carriers is a Whole New Thing" - Experiences of Couples Both Identified as Carriers of Cystic Fibrosis Through a Population-Based Carrier Screening Program in Australia.
    Ioannou L; Delatycki MB; Massie J; Hodgson J; Lewis S
    J Genet Couns; 2015 Dec; 24(6):987-1000. PubMed ID: 25925605
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Community-wide screening for cystic fibrosis carriers could replace newborn screening for the diagnosis of cystic fibrosis.
    Massie J; Forbes R; Dusart D; Bankier A; Delatycki MB
    J Paediatr Child Health; 2007 Nov; 43(11):721-3. PubMed ID: 17924936
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prenatal genetic carrier testing using triple disease screening.
    Eng CM; Schechter C; Robinowitz J; Fulop G; Burgert T; Levy B; Zinberg R; Desnick RJ
    JAMA; 1997 Oct; 278(15):1268-72. PubMed ID: 9333269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluating the benefits of antenatal screening: an alternative approach.
    Shackley P; Cairns J
    Health Policy; 1996 May; 36(2):103-15. PubMed ID: 10158764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The cost-effectiveness of genotyping versus sequencing for prenatal cystic fibrosis carrier screening.
    Avram CM; Dyer AL; Shaffer BL; Caughey AB
    Prenat Diagn; 2021 Oct; 41(11):1449-1459. PubMed ID: 34346064
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cystic fibrosis screening at the Greenville Hospital System.
    Dacus J; Mabie B; Gailey T; Rogers C; Likes C; Metcalf L
    J S C Med Assoc; 2006 Feb; 102(1):14-6. PubMed ID: 16704181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Willingness to pay for antenatal carrier screening for cystic fibrosis.
    Donaldson C; Shackley P; Abdalla M; Miedzybrodzka Z
    Health Econ; 1995; 4(6):439-52. PubMed ID: 8653184
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prenatal cystic fibrosis screening in Mexican Americans: an economic analysis.
    Doyle NM; Gardner MO
    Am J Obstet Gynecol; 2003 Sep; 189(3):769-74. PubMed ID: 14526311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of the CFTR gene-sequencing test for asymptomatic carriers in the Colombian population.
    Andrade E; Díaz J
    Biomedica; 2020 Jun; 40(2):283-295. PubMed ID: 32673457
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The consequences of implementing non-invasive prenatal testing in Dutch national health care: a cost-effectiveness analysis.
    Beulen L; Grutters JP; Faas BH; Feenstra I; van Vugt JM; Bekker MN
    Eur J Obstet Gynecol Reprod Biol; 2014 Nov; 182():53-61. PubMed ID: 25238658
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prenatal screening for cystic fibrosis.
    Mennie ME; Gilfillan A; Compton M; Curtis L; Liston WA; Pullen I; Whyte DA; Brock DJ
    Lancet; 1992 Jul; 340(8813):214-6. PubMed ID: 1353143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The resource implications and service outcomes of genetic services in the context of DNA technology.
    Beech R; Rona RJ; Mandalia S
    Health Policy; 1994 Jan; 26(3):171-90. PubMed ID: 10133130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.